Activation and modulation of the nicotinic receptor

被引:5
作者
Arias, Hugo R. [1 ]
Bouzat, Cecilia [2 ]
机构
[1] Midwestern Univ, Coll Pharm, Dept Pharmaceut Sci, 19555 N 59th Ave, Glendale, AZ 85308 USA
[2] Univ Nacl Sur, CONICET, Inst Invest Bioquim Bahia Blanca, Bahia Blanca, Buenos Aires, Argentina
关键词
Nicotinic receptors; pharmacological properties; gating; allosteric modulators;
D O I
10.3233/JPB-2010-0017
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Nicotinic acetylcholine receptors (AChRs) are the best characterized ion channels representing the Cys-loop receptor superfamily. AChRs have all the machinery to recognize the neurotransmitter ACh and other agonists such as nicotine, and to transduce the agonist-induced conformational changes into the opening of the intrinsic cation channel. The gating machinery couples ligand binding, located at the extracellular portion, to the opening of the ion channel, located at the transmembrane region. The interface between the extracellular and the transmembrane domains is considered one of the most important structural and functional features for the process of gating. And finally, in the prolonged presence of agonists, the AChR becomes desensitized. Several drugs affect the functioning of these receptors. Among them, positive allosteric modulators (PAM) have acquired importance since are novel drugs for several neurological diseases. PAMs do not bind to the orthostetic binding sites but allosterically enhance the activity elicited by agonists by increasing the gating process and/or by decreasing desensitization. Instead, negative allosteric modulators (NAMs) produce the opposite effects. Interestingly, this negative effect is similar to that found for another class of allosteric drugs, i.e. non competitive antagonists (NCAs). However, the main difference between both categories of drugs is based on their distinct binding site locations. Although both NAMs and NCAs do not bind to the agonist sites, NACs bind to sites located in the ion channel, whereas NAMs bind to nonluminal sites. Interestingly, PAMs and NAMs might be developed as potential medications for the treatment of several diseases involving AChRs including, dementia-, skin-, and immunological-related diseases, drug addiction, and cancer. More exciting is the potential combination of specific agonists with PAMs. However, we are still in the beginning of understanding how these compounds act and how these drugs can be used therapeutically.
引用
收藏
页码:53 / 73
页数:21
相关论文
共 183 条
[1]   Role of charged residues in coupling ligand binding and channel activation in the extracellular domain of the glycine receptor [J].
Absalom, NL ;
Lewis, TM ;
Kaplan, W ;
Pierce, KD ;
Schofield, PR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (50) :50151-50157
[2]   Contributions of the non-α subunit residues (loop D) to agonist binding and channel gating in the muscle nicotinic acetylcholine receptor [J].
Akk, G .
JOURNAL OF PHYSIOLOGY-LONDON, 2002, 544 (03) :695-705
[3]   Mammalian Nicotinic Acetylcholine Receptors: From Structure to Function [J].
Albuquerque, Edson X. ;
Pereira, Edna F. R. ;
Alkondon, Manickavasagom ;
Rogers, Scott W. .
PHYSIOLOGICAL REVIEWS, 2009, 89 (01) :73-120
[4]   Radioligand binding characterization of [3H]-A-998679: A novel positive allosteric modulator of α4β2 nAChRs [J].
Anderson, D. J. ;
Vaidyanathan, S. ;
Namovic, M. ;
Donnelly-Roberts, D. ;
Lee, L. ;
Gopalakrishnan, M. .
BIOCHEMICAL PHARMACOLOGY, 2009, 78 (07) :903-904
[5]   Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors [J].
Arias, HR ;
Bhumireddy, P .
CURRENT PROTEIN & PEPTIDE SCIENCE, 2005, 6 (05) :451-472
[6]  
ARIAS HR, 2006, BIOL BIOPHYSICAL ASP, P61
[7]   Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors [J].
Arias, Hugo R. ;
Bhumireddy, Pankaj ;
Bouzat, Cecilia .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2006, 38 (08) :1254-1276
[8]   Different Interaction between the Agonist JN403 and the Competitive Antagonist Methyllycaconitine with the Human α7 Nicotinic Acetylcholine Receptor [J].
Arias, Hugo R. ;
Gu, Ruo-Xu ;
Feuerbach, Dominik ;
Wei, Dong-Qing .
BIOCHEMISTRY, 2010, 49 (19) :4169-4180
[9]   Inhibitory mechanisms and binding site location for serotonin selective reuptake inhibitors on nicotinic acetylcholine receptors [J].
Arias, Hugo R. ;
Feuerbach, Dominik ;
Bhumireddy, Pankaj ;
Ortells, Marcelo O. .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2010, 42 (05) :712-724
[10]   Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions? [J].
Arias, Hugo R. .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2009, 41 (11) :2098-2108